Dossier preparation and structure MCQs With Answer
This quiz set focuses on dossier preparation and structure for M.Pharm students studying Documentation & Regulatory Writing. It covers the Common Technical Document (CTD/eCTD) framework, module-specific contents (Modules 1–5), quality (CMC) documentation, nonclinical and clinical study reports, stability and analytical sections, regional requirements, and practical aspects of compiling and cross-referencing dossiers. The questions are designed to deepen understanding of how regulatory submissions are organized, what documents and summaries are required, and best practices for preparing a complete, compliant dossier for global regulatory filings. Answers are provided to aid revision and exam preparation.
Q1. Which ICH guideline defines the structure and content of the Common Technical Document (CTD)?
- ICH M4
- ICH Q1A
- ICH S6
- ICH E3
Correct Answer: ICH M4
Q2. In the CTD, which module contains region-specific administrative and prescribing information?
- Module 1
- Module 2
- Module 3
- Module 5
Correct Answer: Module 1
Q3. Which CTD module includes the Quality Overall Summary (QOS) and Summaries of Drug Substance and Drug Product?
- Module 2
- Module 3
- Module 4
- Module 5
Correct Answer: Module 2
Q4. Where are full nonclinical study reports (toxicology, pharmacology) located in the CTD?
- Module 3
- Module 4
- Module 5
- Module 1
Correct Answer: Module 4
Q5. Which section label is commonly used in Module 3 for drug substance information in the CTD?
- 3.2.S
- 3.2.P
- 3.2.R
- 3.2.A
Correct Answer: 3.2.S
Q6. What does eCTD stand for and what is its primary purpose?
- electronic Common Technical Document — standardized electronic format for regulatory submissions
- enhanced CTD — a new scientific guideline for dossier content
- electronic Clinical Trial Dossier — for trial registration only
- essential CTD — minimal dossier for generic approvals
Correct Answer: electronic Common Technical Document — standardized electronic format for regulatory submissions
Q7. Which Module of the CTD contains clinical study reports and associated clinical summaries?
- Module 2
- Module 3
- Module 4
- Module 5
Correct Answer: Module 5
Q8. In dossier preparation, what is the primary purpose of the Quality Overall Summary (QOS)?
- Present concise interpretation and critical analysis of all quality data supporting the application
- Provide the full batch manufacturing records for reference
- List all clinical investigators and trial sites
- Serve as the legally binding product label
Correct Answer: Present concise interpretation and critical analysis of all quality data supporting the application
Q9. Which document commonly serves as evidence of a drug substance’s compliance with EU purity standards and may be included in the dossier?
- Certificate of Suitability (CEP)
- Manufacturer’s Bank Statement
- Investigator’s Brochure
- Product Monograph
Correct Answer: Certificate of Suitability (CEP)
Q10. When compiling stability data in the dossier, which of the following is essential to include?
- Study design, storage conditions, time points, analytical methods, and interpretation of results
- Only a pass/fail statement without raw data
- Marketing strategies for product launch
- Only accelerated stability results without long-term data
Correct Answer: Study design, storage conditions, time points, analytical methods, and interpretation of results
Q11. Which of the following best describes the content of Module 2.5 (Clinical Overview) in the CTD?
- Critical, evidence-based synthesis of clinical data, benefit-risk assessment, and integrated interpretation
- Complete set of raw clinical trial data files only
- Administrative forms and regional labeling
- Detailed manufacturing batch records
Correct Answer: Critical, evidence-based synthesis of clinical data, benefit-risk assessment, and integrated interpretation
Q12. For a generic drug (ANDA) dossier, which element is most critical to demonstrate bioequivalence?
- Bioequivalence study reports and comparative dissolution data
- Full nonclinical toxicity program
- Complete proprietary manufacturing process description
- Marketing authorization from another country
Correct Answer: Bioequivalence study reports and comparative dissolution data
Q13. In eCTD submissions, what is the purpose of lifecycle management (sequence numbers)?
- To manage iterative submissions, updates, and modules over time using sequence numbers
- To assign batch numbers for manufacturing
- To list investigators chronologically
- To encrypt the dossier for confidentiality
Correct Answer: To manage iterative submissions, updates, and modules over time using sequence numbers
Q14. Which of the following is a correct pairing of CTD module and its typical contents?
- Module 3 — Chemistry, Manufacturing and Controls (CMC) documentation
- Module 4 — Product labeling and regional prescribing information
- Module 1 — Nonclinical study reports and toxicology
- Module 5 — Administrative forms and certificates
Correct Answer: Module 3 — Chemistry, Manufacturing and Controls (CMC) documentation
Q15. What is the role of the Module 2 Nonclinical Overview in a dossier?
- Summarize nonclinical studies, integrate findings, and provide a toxicology risk assessment
- Provide the full clinical study reports
- Contain marketing and commercial forecasts
- List only the manufacturing equipment used
Correct Answer: Summarize nonclinical studies, integrate findings, and provide a toxicology risk assessment
Q16. Which of the following best practices improves readability and review efficiency of a dossier?
- Clear cross-referencing, consistent file naming, an organized table of contents, and concise executive summaries
- Including every raw instrument output without interpretation
- Using multiple incompatible file formats and no bookmarks
- Hiding critical data in appendices without navigation aids
Correct Answer: Clear cross-referencing, consistent file naming, an organized table of contents, and concise executive summaries
Q17. For biological products, which dossier section typically contains characterization of the molecule, cell-line information, and viral safety data?
- Module 3 — Biological quality (3.2.S & 3.2.P adapted for biologics)
- Module 4 — Clinical pharmacology
- Module 2 — Administrative forms
- Module 1 — Environmental risk only
Correct Answer: Module 3 — Biological quality (3.2.S & 3.2.P adapted for biologics)
Q18. What distinguishes a dossier “variation” from a new marketing authorization application?
- Variation is a post-approval change to an existing authorization; new application requests initial approval
- Variation is only for labeling changes and never for manufacturing
- New application is only for generics; variation is for biologics
- Variation cancels the original authorization
Correct Answer: Variation is a post-approval change to an existing authorization; new application requests initial approval
Q19. When preparing Module 3 impurity profiles, which of the following should be included in the dossier?
- Identification, qualification, analytical control strategy, and justification for acceptance criteria
- Only the highest detected impurity name without data
- Marketing plans for impurity reduction
- Clinical investigator opinions on impurities
Correct Answer: Identification, qualification, analytical control strategy, and justification for acceptance criteria
Q20. Which of the following statements about Module 1 in international dossiers is correct?
- Module 1 is region-specific and varies by authority (e.g., FDA, EMA) containing administrative, labeling, and regional forms
- Module 1 is identical in all regions and standardized by ICH
- Module 1 contains only clinical study reports
- Module 1 is optional and usually omitted
Correct Answer: Module 1 is region-specific and varies by authority (e.g., FDA, EMA) containing administrative, labeling, and regional forms
